Background
The Alaska Supreme Court revived the State’s central claim against Albertsons, Safeway, Kroger, Fred Meyer, and related companies over their alleged role in the opioid epidemic. The State alleges that the retailers’ pharmacies ignored duties imposed by federal and Alaska controlled-substances law to monitor prescriptions, investigate warning signs, report suspicious activity, and prevent diversion. According to the complaint, pharmacies filled prescriptions despite red flags, distributed quantities disproportionate to local populations, and failed to maintain effective controls even after receiving regulatory guidance about diversion risks.
The complaint connects those alleged practices to collective harms across Alaska: overdose deaths, illicit opioid use, pressure on hospitals and Medicaid, infectious disease associated with injection drug use, demands on law enforcement, and increased foster-care placements. It asserts claims under the Alaska Unfair Trade Practices and Consumer Protection Act, commonly called the UTPA, and the common law of public nuisance. The public-nuisance doctrine addresses a substantial and unreasonable interference with a right shared by the public, rather than merely an injury suffered by particular individuals.
The superior court dismissed both claims on the pleadings. It concluded that the pharmacies’ conduct was exempt from the UTPA because pharmacy operations are regulated under other state law. It also reasoned that the sale and misuse of otherwise lawful products did not interfere with a public right and that products-liability law, not nuisance law, supplied the appropriate framework. On appeal, the supreme court reviewed the dismissal de novo, accepted the complaint’s factual allegations as true, and asked only whether the State had alleged legally viable claims.
The Court’s Holding
The court reversed dismissal of the public-nuisance claim. Alaska law does not restrict public nuisance to interference with land, public ways, or natural resources. Public health and safety are collective rights capable of supporting the claim. The State plausibly alleged that widespread failures by pharmacies acting as the final gatekeepers for prescription opioids substantially and unreasonably interfered with those rights. The pharmacies’ preexisting statutory and regulatory duties were critical: alleged violations made this case different from an attempt to impose liability merely because a lawful product later caused harm.
The court also rejected a categorical products exception. A public-nuisance action may involve product sales when the challenged conduct otherwise satisfies Alaska’s nuisance elements. Here, the alleged wrong was not the mere presence of nondefective opioids in commerce, but the manner in which pharmacies allegedly dispensed them without required controls. The ruling does not establish liability or causation; it holds that the allegations are sufficient to proceed beyond Civil Rule 12(b)(6).
On the UTPA claim, the court largely affirmed but preserved one theory. It held that the pharmacy regulatory system qualifies as “ongoing, careful regulation,” and defendants need not produce examples of actual enforcement to establish that part of the statutory exemption. Alaska law specifically prohibits most of the complained-of conduct, including inadequate compliance programs, failure to investigate suspicious orders, filling suspicious prescriptions, and inadequate due diligence. Those allegations therefore remain exempt from the UTPA. But the alleged public promotion of compliance efforts, creating a false impression that the pharmacies were meeting their duties and combating diversion, was not shown to be specifically prohibited by pharmacy regulations. That deception theory may proceed.
Key Takeaways
- Alaska public-nuisance law protects collective public-health and public-safety interests and is not confined to property, roads, waterways, or natural resources.
- Product sales are not categorically outside public-nuisance law when the defendant allegedly violated independent legal duties and directly controlled the final distribution step.
- The UTPA’s regulated-conduct exemption does not require proof of prior enforcement activity, but it applies only when the governing scheme prohibits the specific conduct alleged.
- A distinct deceptive-publicity theory may survive even when operational failures involving the same regulated business are exempt from the UTPA.
Why It Matters
The decision gives Alaska public entities a potentially consequential route to seek equitable abatement of widespread health harms without forcing those claims into an individual products-liability model. At the same time, the court tied that route to familiar limiting principles: an identified public right, unreasonable interference, causation, and—on these allegations—specific duties imposed independently by controlled-substances law. Alaska practitioners defending regulated businesses should therefore test not only whether a product is lawful, but also whether the complaint identifies violated gatekeeping obligations and genuinely collective harm.
For UTPA litigation, the opinion sharpens both steps of the regulated-conduct exemption. A comprehensive enforcement framework can qualify without a history of enforcement examples, yet courts must compare each alleged practice against what the separate regulatory scheme actually prohibits. Pleading distinct representations or promotional conduct may change the result. The remand now permits factual development; the State still must prove the pharmacies’ conduct, causation, unreasonable interference, and entitlement to relief.